Here’s a bold statement: the future of lung cancer treatment might be closer than we think, and it’s coming from an unexpected combination. But here’s where it gets controversial—what if a new therapy could significantly improve outcomes for patients with PD-L1–negative non–small cell lung cancer (NSCLC), a group that has historically faced limited treatment options? Early data from the STK-012-101 trial suggest that the combination of STK-012, pembrolizumab (Keytruda), and chemotherapy could be a game-changer. Let’s dive into the details and explore why this might just be the breakthrough we’ve been waiting for.
The phase 1a/1b STK-012-101 trial (NCT05098132) presented at the 2025 SITC Annual Meeting revealed promising results for patients with PD-L1–negative nonsquamous NSCLC. This combination therapy not only demonstrated early efficacy but also showed a manageable safety profile, addressing a critical unmet need in this challenging patient population. And this is the part most people miss—despite advances in lung cancer treatment, PD-L1–negative NSCLC, especially with immune resistance mutations, remains a stubborn adversary. Could this new approach finally turn the tide?
Key Findings: What Makes This Study Stand Out?
- Impressive Response Rates: At a median follow-up of 4 months, the regimen achieved a 55% objective response rate (ORR) in all evaluable patients (n = 22), with a disease control rate (DCR) of 96%. Even in patients with a PD-L1 tumor proportion score (TPS) below 1% (n = 18), the ORR was 50%, and the DCR remained high at 94%.
- Deepening Responses Over Time: Perhaps most excitingly, responses deepened over time, even in patients with challenging mutations like STK11 and KEAP1. By the clinical cutoff date of September 15, 2025, 15 out of 22 patients were still on treatment, suggesting durable benefits.
- Manageable Safety Profile: No dose-limiting toxicities were reported, and most treatment-related adverse effects (TRAEs) were reversible. While one grade 4 TRAE (neutropenia) was noted, no grade 5 toxicities occurred, and no patients discontinued treatment due to side effects. Importantly, there were no significant interleukin-2 (IL-2) related TRAEs, a common concern with similar therapies.
Why This Matters: A Closer Look at the Implications
Boldly highlighting a potential controversy—could this combination therapy redefine the standard of care for PD-L1–negative NSCLC? While the results are early, they are undeniably encouraging. Dr. Adam J. Schoenfeld of Memorial Sloan Kettering Cancer Center noted that if these findings are replicated in larger studies, they could reshape the treatment landscape. But here’s the question: are we ready to embrace this as the next big step, or do we need more data to be convinced?
Study Design: How Did They Get Here?
The trial was divided into two parts: phase 1a focused on 6 to 10 treatment-naive patients with stage IV nonsquamous NSCLC, regardless of PD-L1 expression, while phase 1b enrolled 20 to 40 patients with a PD-L1 TPS below 1%. Patients received STK-012 (2.25 mg subcutaneously), pembrolizumab (200 mg intravenously), pemetrexed (500 mg/m²), and carboplatin (AUC 5) in a carefully structured regimen. The primary endpoint was safety, with ORR as a key secondary endpoint.
Patient Demographics: Who Benefited?
Among the 22 efficacy-evaluable patients, the median age was 69, with a slight majority (55%) being male. Most patients (73%) were current or former smokers, and 82% had a PD-L1 TPS under 1%. Notably, 77% had non-mucinous adenocarcinoma, and several patients had challenging mutations like STK11, KEAP1, and KRAS, which are often associated with poorer outcomes. Despite these complexities, the therapy showed promise across the board.
Safety Profile: What Were the Side Effects?
The combination therapy was well-tolerated, with grade 1/2 TRAEs occurring in 52% of patients and grade 3/4 TRAEs in 28%. Common side effects included nausea, fatigue, rash/dermatitis, and injection site reactions, all of which were manageable. Importantly, there were no significant IL-2 related TRAEs, a testament to the therapy’s refined design.
What’s Next: The Road Ahead
The phase 2 trial, SYNERGY-101, is already underway, recruiting 105 treatment-naive patients with stage IIIB/IIIC or IV nonsquamous NSCLC and a PD-L1 TPS below 1%. Patients will be randomized to receive STK-012 at different doses in combination with pembrolizumab, pemetrexed, and carboplatin, or the standard therapy alone. The primary endpoint remains ORR, with blinded independent central review to ensure unbiased results.
Final Thoughts: A Call to Action
This early data is undeniably exciting, but it also raises important questions. Is this the breakthrough PD-L1–negative NSCLC patients have been waiting for, or is it too early to celebrate? What do you think? Could this combination therapy become the new standard, or are there still hurdles to overcome? Share your thoughts in the comments below—let’s keep the conversation going and explore the possibilities together.
